SeHCAT

Template:Chembox E number

SeHCAT

Names
IUPAC name (75Se)-2-[[[[(3α,5α,7α,12α,20S)-3,7,12-trihydroxy-20-methylpregnan-21-yl]seleno]acetyl]amino]ethanesulfonic acid,
Other names 23-Seleno-25-homo-tauro-cholic acid; Selenium homocholic acid taurine; Tauroselcholic acid
Identifiers
CAS Number	75018-71-2 Y
3D model (JSmol)	Interactive image
ECHA InfoCard
PubChem CID	123829
SMILES C[C@H](C[75Se]CC(NCCS(O)(=O)=O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C
Properties
Chemical formula	C26H45NO7SSe
Molar mass	594.68 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is YN ?)
Infobox references

WikiDoc Resources for SeHCAT
Articles
Most recent articles on SeHCAT Most cited articles on SeHCAT Review articles on SeHCAT Articles on SeHCAT in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on SeHCAT Images of SeHCAT Photos of SeHCAT Podcasts & MP3s on SeHCAT Videos on SeHCAT
Evidence Based Medicine
Cochrane Collaboration on SeHCAT Bandolier on SeHCAT TRIP on SeHCAT
Clinical Trials
Ongoing Trials on SeHCAT at Clinical Trials.gov Trial results on SeHCAT Clinical Trials on SeHCAT at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on SeHCAT NICE Guidance on SeHCAT NHS PRODIGY Guidance FDA on SeHCAT CDC on SeHCAT
Books
Books on SeHCAT
News
SeHCAT in the news Be alerted to news on SeHCAT News trends on SeHCAT
Commentary
Blogs on SeHCAT
Definitions
Definitions of SeHCAT
Patient Resources / Community
Patient resources on SeHCAT Discussion groups on SeHCAT Patient Handouts on SeHCAT Directions to Hospitals Treating SeHCAT Risk calculators and risk factors for SeHCAT
Healthcare Provider Resources
Symptoms of SeHCAT Causes & Risk Factors for SeHCAT Diagnostic studies for SeHCAT Treatment of SeHCAT
Continuing Medical Education (CME)
CME Programs on SeHCAT
International
SeHCAT en Espanol SeHCAT en Francais
Business
SeHCAT in the Marketplace Patents on SeHCAT
Experimental / Informatics
List of terms related to SeHCAT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

SeHCAT is the usual name for 23-seleno-25-homo-tauro-cholic acid (selenium homocholic acid taurine or tauroselcholic acid). It is used in a clinical test to diagnose bile acid malabsorption.

Development

SeHCAT is a taurine-conjugated bile acid analog which was synthesized for use as a radiopharmaceutical to investigate in vivo the enterohepatic circulation of bile salts. By incorporating the gamma-emitter ⁷⁵Se into the SeHCAT molecule, the retention in the body or the loss of this compound into the feces could be studied easily using a standard gamma camera, available in most clinical nuclear medicine departments.

SeHCAT has been shown to be absorbed from the gut and excreted into the bile at the same rate as cholic acid, one of the major natural bile acids in humans. It undergoes secretion into the biliary tree, gallbladder and intestine in response to food, and is reabsorbed efficiently in the ileum, with kinetics similar to natural bile acids. It was soon shown to be the most convenient and accurate method available to assess and measure bile acid turnover in the intestine. SeHCAT testing was commercially developed by Amersham International Ltd (Amersham plc is now part of GE Healthcare Medical Diagnostics division) for clinical use to investigate malabsorption in patients with diarrhea. This test has replaced ¹⁴C-labeled glycocholic acid (or taurocholic acid) breath tests and fecal bile acid measurements, which now have no place in the routine clinical investigation of malabsorption.

Procedure

A capsule containing radiolabelled ⁷⁵SeHCAT (with 370kBq of Selenium-75 and less than 0.1 mg SeHCAT) is taken orally. The physical half life of ⁷⁵Se is approximately 118 days; activity is adjusted to a standard reference date.

Patients are often fasted before taking the capsule and swallow water to ensure passage of the capsule into the gastrointestinal tract. The effective dose of radiation for an adult given 370kBq of SeHCAT is 0.26mSv. (For comparison, the radiation exposure from an abdominal CT scan is quoted at 5.3mSv and annual background exposure in the UK 1-3mSv.) Measurements were originally performed with a whole body counter but are usually performed now with an uncollimated gamma camera. The patient is scanned supine or prone with anterior and posterior acquisition from head to thigh 1 to 3 hours after taking the capsule. Scanning is repeated after 7 days. Background values are subtracted and care must be taken to avoid external sources of radiation in a nuclear medicine department.

From these measurements, the percent retention of SeHCAT at 7 days is calculated. A 7-day SeHCAT retention value greater than 15% is considered to be normal, with values less than 15% signifing excessive bile acid loss, as found in bile acid malabsorption.

With more frequent measurements, it is possible to calculate SeHCAT retention whole body half-life; this is not routinely measured in a clinical setting. A half-life of greater than 2.8 days has been quoted as normal.

Clinical use

The SeHCAT test is used to investigate patients with suspected bile acid malabsorption, who usually experience chronic diarrhea, often passing watery feces 5 to 10 times each day. When ileum has been removed following surgery, or is inflamed in Crohn's disease, the 7-day SeHCAT retention usually is abnormal, and most of these patients will benefit from treatment with bile acid sequestrants. The enterohepatic circulation of bile acids is reduced in these patients with ileal abnormalities and, as the normal bile acid retention exceeds 95%, only a small degree of change is needed. Bile acid malabsorption can also be secondary to cholecystectomy, vagotomy and other disorders affecting intestinal motility or digestion such as radiation enteritis, celiac disease and small intestinal bacterial overgrowth.

A similar picture of chronic diarrhea, an abnormal SeHCAT retention and a response to bile acid sequestrants, in the absence of other disorders of the intestine, is characteristic of idiopathic bile acid malabsorption – also called primary bile acid diarrhea. These patients are frequently misdiagnosed as having the irritable bowel syndrome, as clinicians fail to recognize the condition, do not think of performing a SeHCAT test, or do not have it available.

There have been at least 18 studies of the use of SeHCAT testing in diarrhea-predominant irritable bowel syndrome patients. When these data were combined, 32% of 1223 patients had a SeHCAT 7-day retention of less than 10%, and 80% of these reported a response to cholestyramine, a bile acid sequestrant.